Comparison 2. Degarelix versus androgen suppression therapy (GnRH agonists or maximum androgen suppression therapy): subgroup analysis based on different doses.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Serious adverse events	9	2951	Risk Ratio (M‐H, Random, 95% CI)	0.80 [0.63, 1.03]
2.1.1 Degarelix 240 mg/80 mg	7	1466	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.39, 1.14]
2.1.2 Degarelix 240 mg/160 mg	1	403	Risk Ratio (M‐H, Random, 95% CI)	0.85 [0.51, 1.42]
2.1.3 Degarelix 240 mg/480 mg	2	1082	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.64, 1.26]
2.2 Quality of life	3	2887	Std. Mean Difference (IV, Random, 95% CI)	0.06 [‐0.05, 0.18]
2.2.1 Degarelix 240 mg/80 mg	2	2040	Std. Mean Difference (IV, Random, 95% CI)	‐0.03 [‐0.33, 0.28]
2.2.2 Degarelix 240 mg/480 mg	1	847	Std. Mean Difference (IV, Random, 95% CI)	0.10 [‐0.04, 0.24]
2.3 Injection site pain	8	2670	Risk Ratio (M‐H, Random, 95% CI)	15.68 [7.41, 33.17]
2.3.1 Degarelix 240 mg/80 mg	6	1286	Risk Ratio (M‐H, Random, 95% CI)	14.94 [4.48, 49.81]
2.3.2 Degarelix 240 mg/160 mg	1	302	Risk Ratio (M‐H, Random, 95% CI)	61.20 [3.82, 979.36]
2.3.3 Degarelix 240 mg/480 mg	2	1082	Risk Ratio (M‐H, Random, 95% CI)	15.24 [8.50, 27.31]